Oct. 5, 2023

Renee Wegrzyn, PhD, Director of the Advanced Research Projects Agency for Health (ARPA-H), announced funding of three new programs to support the Cancer Moonshot during a Cancer Moonshot Mission Update hosted by POLITICO. The programs are:

  • Targeted Hybrid Oncotherapeutic Regulation (THOR): $45 million to Rice University to develop a minimally invasive implant that senses and responds with a specific treatment and will trigger the immune system against tumors.
  • Synthetic Programmable bacteria for Immune-directed Killing in tumor Environments (SPIKEs): Up to $19 million to the University of Missouri to develop an inexpensive and safe therapy using bacteria specifically selected for tumor-targeting.
  • Cancer and Organ Degradome Atlas (CODA): Up to $50 million to the Georgia Institute of Technology to map cancer cell biomarkers to drastically improve multi-cancer early detection and streamline clinical intervention when tumors are still small.

Danielle Carnival, PhD, Deputy Assistant to the President for the Cancer Moonshot, reiterated the collaboration and non-duplicative efforts among ARPA-H and the National Cancer Institute during the update. She also emphasized the relationship between innovative technology and access to care, emphasizing preventive care and early detection.

For more information, contact Katie Grady, American College of Radiology® Director of Government Affairs.


Related ACR News

  • ACR Advises Changes to Washington State PAD Report

    ACR urged the WA State Health Technology Clinical Committee to not act on the draft report that would limit coverage of endovascular procedures for PAD.

    Read more
  • ACR Releases Impact Tables for 2026 MPFS Proposed Rule

    The tables cover specific proposed changes in reimbursement rates between 2025 and 2026 for each CPT® code.

    Read more
  • Take Action: Contact Your US Senators to Cosponsor ROOT Act

    Support the ROOT Act—Senate cosponsors needed to fix CMS issues with imaging AUC under PAMA. College member advocacy is key.

    Read more